King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY®
BRISTOL, Tenn. and SAN MATEO, Calif., Dec. 27, 2010 /PRNewswire/ -- King Pharmaceuticals®, Inc. (NYSE: KG) and Pain Therapeutics®, Inc. (Nasdaq: PTIE) today announced that King has resubmitted a New Drug Application (NDA) for REMOXY® (oxycodone) to the U.S. Food and Drug Administration (FDA) in response to a Complete Response letter received by Pain Therapeutics in December 2008. This is a Class 2 resubmission with a six month review cycle.
REMOXY® is a twice daily, long-acting formulation of oral oxycodone for moderate to severe pain requiring continuous, around-the-clock opioid treatment for an extended period of time. REMOXY® was developed by Pain Therapeutics, using DURECT Corporation's (Nasdaq: DRRX) ORADUR® technology, to help address the growing problem of non-medical use of prescription opioids. REMOXY® is comprised of a high-viscosity, liquid formulation in a hard gelatin capsule that is designed to provide steady, around-the-clock pain relief, while resisting common methods of tampering intended to result in the rapid release of oxycodone.
About King Pharmaceuticals®, Inc.
King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. King's wholly owned subsidiary, Alpharma, LLC, is also a leader in the development, registration, manufacture, and marketing of pharmaceutical products for food-producing animals. On October 11, 2010, King entered into an agreement and plan of merger with Pfizer Inc. pursuant to which Pfizer agreed to commence a tender offer to purchase all of the outstanding shares of common stock of King for $14.25 per share net to the seller in cash. The tender offer is ongoing.
About Pain Therapeutics®, Inc.
Pain Therapeutics®, Inc. is a biopharmaceutical company that develops novel drugs. In addition to REMOXY®, the Company has three other drug candidates in clinical programs. These include a novel monoclonal antibody-based treatment against metastatic melanoma. The Company is also developing a new treatment for patients with hemophilia, a genetic disorder in which patients are unable to stop bleeding.
Related links:
http://www.KingPharm.com
http://www.PainTrials.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). When used in this press release, the words "intend", "expect," "believe" and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include statements concerning, among other items, the Companies' expectations regarding the FDA's review of the REMOXY® NDA and the tamper-resistance capabilities of REMOXY® and ORADUR® Technology. King Pharmaceuticals®, Inc. and Pain Therapeutics®, Inc. disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of each of the Companies' Annual Reports on Form 10-K for the fiscal year ended December 31, 2009, and their Quarterly Reports on Form 10-Q for the quarter ended September 30, 2010, each of which is on file with the U.S. Securities and Exchange Commission.
EXECUTIVE OFFICES
KING PHARMACEUTICALS®, INC.
501 FIFTH STREET, BRISTOL, TN 37620
PAIN THERAPEUTICS®, INC.
2211 BRIDGEPOINTE PARKWAY, SUITE 500, SAN MATEO, CA 94404
REMOXY® is a registered trademark of Pain Therapeutics®, Inc.
King Pharmaceuticals Contact:
Jack Howarth, Vice President, Investor Relations
908-429-8350
Pain Therapeutics Contact:
Judy Ishida, Administrative Manager
650-645-1924
Media Contact:
Laurie Masonson, Ruder Finn, Inc.
212-583-2793
SOURCE King Pharmaceuticals(R), Inc.
Back to top
RELATED LINKS
http://www.kingpharm.com
http://www.paintrials.com